An early-stage biotechnology company focused on aging research. The team has decades of experience in aging science and has collectively authored more than 200 papers. The company operates a platform that develops drug candidates intended to slow aging, reportedly achieving a 20% success rate in advancing candidates. Planned work includes testing the candidates in aging mice. The executive chairman previously served as chief executive officer of Sangamo Therapeutics, a biopharma company.